Powering research breakthroughs
We invest in the most promising research to turn ideas into life-changing therapies and lead the way to cures.
A New Shot on Goal for Cell Therapies In T1D
Eledon Pharmaceuticals announces new funding from the T1D Fund and the launch of their clinical trial for tegoprubart in T1D.
Top Type 1 Diabetes Advances of Fiscal Year 2023
Breakthrough T1D highlights the top type 1 diabetes advances we've seen during fiscal year 2023, including cures and life-improving therapies.
Breakthrough T1D Collaboration Leads to Next-Generation Cell Therapy Research
Aspect and Novo Nordisk announce a partnership, using Aspect’s bioprinting technology and Novo Nordisk’s expertise, to develop treatments for diabetes.
Cell therapy moves forward across the pipeline
Beta cell replacement therapies aim to overcome the obstacles to realize their potential, but several approaches are making them a thing of the past.
Verapamil Slows Type 1 Diabetes Progression in Newly Diagnosed Children and Teens
The CLVer study found that newly diagnosed individuals on verapamil were making more insulin one year after diagnosis than those on placebo.
“I Really Love Type 1 Diabetes Research, and I’m Not Going Back”
A goal of David Alagpulinsa, Ph.D., is to contribute to a treatment that makes people with type 1 diabetes live like everyone—without T1D—else.
Breakthrough T1D Timeline: Stem Cell Therapies
Stem cells have the potential to lead to treatments for type 1 diabetes, but it has taken Breakthrough T1D more than 20 years to get to this point.
Vertex Provides an Update on the VX-880 Clinical Trial
Vertex provides an update on their Phase 1/2 Clinical Trial for VX-880, including data from three participants and details around the clinical hold.
The First Gene-Edited Cell Replacement Therapy Takes a Step Forward
The first person has received ViaCyte and CRISPR's cell replacement therapy.
